Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids by Vučinić, Slavica et al.
178
Original article DOI: 10.2478/aiht-2018-69-3096
 
Clinical and analytical experience of the National Poison 
Control Centre with synthetic cannabinoids
Slavica Vučinić1, Vesna Kilibarda1, Snežana Đorđević1, Dragana Đorđević1, Nataša Perković-
Vukčević1, Gordana Vuković-Ercegović1, Biljana Antonijević2, Marijana Ćurčić2,  
Evica Antonijević2, and Gordana Brajković1
National Poison Control Centre, Military Medical Academy, Medical Faculty University of Defense1, University of 
Belgrade Faculty of Pharmacy, Department of Toxicology “Akademik Danilo Soldatović”2, Belgrade, Serbia
[Received in January 2018; Similarity Check in January 2018; Accepted in May 2018]
A rising number of patients are being treated for overdosing with new psychoactive substances (NPS) available at the 
illegal drug market in Serbia. The aim of this study was to report clinical and analytical experience of the National Poison 
Control Centre of Serbia (NPCC) with synthetic cannabinoids (SCs) and point to the NPS available at the illegal drug 
market in our country. From January 2013 to December 2016, 58 patients (aged between 14 and 25) were treated for the 
effects of synthetic cannabinoids at the NPCC. Tachycardia was established in 53, mydriasis in 31, somnolence, nausea, 
vomiting, and agitation in 16, dizziness in 10, disorientation in 9, dyspnoea and chest pain in 4, and loss of consciousness, 
pallor, paraesthesia, muscle twitches, and short-term memory impairment in 2 patients. After receiving symptomatic and 
supportive treatment in the emergency ward, all patients had fully recovered within 8 h and were discharged shortly 
afterwards. Another part of the study was focused on the analysis of the products known under their local street names 
as “Biljni tamjan” (herbal incense), “Beli slez”, and “Rainbow Special” and the analysis of urine sampled from the patients 
with gas chromatography - mass spectrometry and high performance liquid chromatography. The detected synthetic 
cannabinoids were AB-PINACA, JWH-018, JWH-122, JWH-210, 5F-AKB48, and MDMB-CHMICA in herbal products 
and AB-FUBINACA, AB-CHMINACA, and MDMB-CHMICA in the urine samples. Our findings have shown the great 
capacity of NPCC to I) monitor NPS abuse in Serbia, II) reliably detect SCs in illicit products and biological samples, 
and III) clinically manage the adverse effects in their users. Future commitments of the NPCC will include systematic 
collection of relevant data on SCs and their adverse effects, detection of changes in purity and composition of the controlled 
NPS-based products, and raising the public awareness of NPS to improve the effectiveness of the national Early Warning 
System.
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The term new psychoactive substances (NPS) refers to 
“any new narcotic or psychotropic drug that is not controlled 
by the UN Convention on Narcotic Drugs from 1961 or the 
Convention on Psychotropic Substances from 1971, but 
which may pose a public health threat similar to controlled 
psychoactive substances” (1). Seventeen years ago, only a 
handful of NPS were available on the market as “new, legal, 
and safe” alternatives to illegal drugs (2). At that time they 
were sold openly in head shops, on the street, or on the 
Internet under the guise of “air fresheners”, “bath salts”, 
“designer drugs”, “herbal highs”, “research chemicals”, 
“plant feeders”, or even “food supplements” (3-5). Soon 
after that, NPS saw dramatic expansion in the global drug 
market. By the end of 2016, their number increased to over 
620 and is still growing, with one or two NPS appearing 
every week. Although they are not under international 
control, NPS have become a global problem, and many 
countries have already issued permanent or temporary 
control measures. This heterogeneous group of psychoactive 
substances includes over 180 synthetic cannabinoids, 104 
synthetic cathinones, phenethylamines, piperazines, 
tryptamines, arylcyclohexyamines and other substances that 
mimic the effects of their parallels from the controlled 
psychoactive substances (PAS) but with higher potency and 
duration of effects (2, 6).
Synthetic cannabinoids or synthetic cannabinoid 
receptor agonists (SCRAs), the largest, most frequently 
used and seized group of NPS, was developed a few decades 
ago from the research of the endocannabinoid system or 
from research for new analgesics. They appeared on the 
market in 2005 under the street name “Spice”, “herbal 
smoking mixtures”, or “air fresheners” that do not contain 
cannabis, but when smoked they cause similar effects. Since 
they first appeared in Europe, SCRAs became the largest 
group of NPS monitored by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) and 
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EUROPOL through the EU Early Warning System (EWS) 
operating through the Reitox network, which currently 
includes 28 EU member states, Norway, the European 
Commission, and the candidate countries (7, 8).
Whilst they are cannabinoid receptor type 1 (CB1) 
agonists functionally similar to Δ-9-tetrahydrocannabinol 
(THC), SCRAs produce more severe and longer lasting 
health effects due to 20 to 100 times higher potency. The 
mechanisms of their toxicity are not fully elucidated, yet it 
is possible that their physiological effects are not limited to 
CB receptors.
Since 2008, when the forensic services in Germany and 
Austria detected the first synthetic cannabinoid, JWH-018 
in a “Spice” product, their number and chemical diversity 
has changed considerably (2-7). Most SCRAs are 
manufactured by chemical companies in China and India 
and shipped as bulk powders to Europe. Although the purity 
of bulk powders is seldom determined, reports from South 
Korea range between 75 % and 90 % (5). Due to the high 
potency of SCRAs, one kg of powder may be used to 
produce thousands of doses.
The bulk powder is then dissolved in acetone and 
methanol, sprayed onto a plant material (usually Damiana 
and Lamiaceae herbs), dried, and packed (5). The products 
analysed in this study usually contained herbs such as 
Mentha and Thymus, sprayed with a SCRA mixture (11, 
12).
The number of users boomed as the media started to 
advertise NPS as “merely relaxing herbal blends”. They 
were smoked or inhaled as “herbal incense” or “liquid 
incense” in cartridges for e-cigarettes. Recent police 
seizures reported that now they take the form of powder or 
tablet.
Chemical classification of synthetic cannabinoids 
includes classical cannabinoids (tetrahydrocannabinol, 
other chemical constituents of cannabis and their structurally 
related synthetic analogues, e.g. AM-411, HU-210, etc.); 
non-classical cannabinoids [cyclohexylphenols or 
3-arylcyclohexanols (e.g. CP-55, CP-47,497)]; hybrid 
cannabinoids [combinations of classical and non-classical 
cannabinoids (e.g. AM-4030)]; aminoalkylindoles 
[naphtoylindoles (e.g. JWH-015, JWH-018, JWH-073, 
JWH-122, JWH-210), phenylacetylindoles (e.g. JWH-250, 
J W H - 2 5 1 ) ,  b e n z o y l i n d o l e s  ( e . g .  A M - 6 9 4 ) , 
naphtylmethylindoles (e.g. JWH-184), cyclopropoylindoles, 
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Figure 1 Chemical structure of synthetic cannabinoids
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Prevalence data have shown notable differences 
between the European and US drug markets. Although the 
number of users is declining in Europe and US in general, 
there are specific groups (clubbers, internet users, etc.) who 
use SCRAs more than others (5). According to the 2012 
Global Drug Survey, the prevalence in the UK among all 
respondents was 3.3 % and among regular clubbers 5 % (2, 
5, 6).
The Early Warning System in Serbia is active since 
2016, with the National Poison Control Centre (NPCC) as 
one of its key subjects (Figure 2) responsible for the 
diagnosis and treatment of poisoning, defining the clinical 
picture related to NPS, risk assessment, and reporting to 
the National Monitoring Centre for Drugs and Drug 
Addiction in Serbia. This EWS is to report to the EU EWS 
annually or according to the risk assessment (15).
The aim of our study was to report clinical and analytical 
experience of the NPCC with synthetic cannabinoids and 
point to the new psychoactive substances (NPS) available 
at the illegal drug market in our country.
PATIENTS AND METHODS
Our study spanned from January 2013 to December 
2016 and included 58 patients aged between 14 and 25 years 
(5 in 2013, 14 in 2014, 36 in 2015, and 3 in 2016) who were 
treated for the effects of SCRAs at the Department of 
(e.g. UR-144, XRL-11), adamantoylindoles (e.g. AM-
1248), and indole carboxamides (e.g. STS-135)]; eicosanoids 
[anandamide (e.g. AM-356)]; and others [diarylpyrazoles, 
naphtoylpyrroles (e.g. JWH-307), naphthylmethylindenes 
(e.g. JWH-176), and indazole carboxamides (e.g. 
APINACA)] (11) (Figure 1).
However, their full pharmacological profiles are 
unavailable, and the clinical spectrum is therefore still not 
complete. Beside the effects on the central nervous system 
(agitation, confusion, hallucinations, tremor, convulsions, 
muscle spasms, paranoia, psychosis a.k.a. “spiceophrenia”, 
somnolence, and suicidal thoughts and actions), they are 
associated with cardiovascular effects (tachycardia, 
hypertension, chest pain, and dyspnoea), nausea, vomiting, 
hypokalaemia, high creatine phosphokinase, and more 
recently with cerebrovascular infarction, acute renal failure, 
and acute myocardial infarction in previously healthy young 
people, including fatalities (5-13).
For example, MDMB-FUBINACA was responsible for 
more than 600 poisonings, including 15 fatalities in Russia 
(2). In 2015, hospitals in the United States reported a rise 
in the number of poisonings with ADB-FUBINACA 
requiring emergency treatment (2). EMCDDA issued public 
health alerts about MDMB-CHMICA in 2016, as poisonings 
and even fatalities were reported in several countries in 
Europe and the USA. In the first nine months of 2017, 
poison control centres in the USA reported 1837 poisonings, 
and called for real-time monitoring (14).
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Figure 2 Organisational structure of partners in the Early Warning System of Serbia
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Reanimation and Triage (DRT) of the National Poison 
Control Centre (NPCC) in Belgrade, Serbia. All of them 
reported the use of “synthetic cannabinoids” or “herbal 
incense”, sometimes under the brand or street names “Biljni 
tamjan”, “Beli slez”, “Rainbow Special”, “Bad-Mad”, 
“Sharp Blueberry”, “Sharp-Aroma”, “Galaxy”, “Black 
Grass”, and “Luminated”, which they obtained from friends, 
in tobacco shops, or online as natural herbal products and 
air fresheners and consumed them by smoking or inhaling 
the smoke. We took their medical history, examined them, 
and administered symptomatic and supportive treatment.
We also took 10 samples of herbal material and 10 urine 
samples from patients who agreed to do it. Herbal samples 
were macerated in 1 mL of methanol, and 1 µL of the 
methanol solution was injected into the instrument. The 
compound of interest was separated from the matrix on a 
DB5 column (30 m x 0.25 mm I.D. 0.25 µm thickness, 
Thermo Scientific, Waltham, Massachusetts, USA). The 
column temperature was initially set at 80 °C and held 
isothermal for 2 min after injection, then ramped to 260 °C 
at a rate of 20 °C min-1 and held isothermal for 10 min, then 
again ramped to 300 °C at a rate of 5 °C min-1 and kept 
there for 5 min. The injector temperature was 260 °C, with 
split gas flow of 50 mL min-1. Carrier gas flow was 
1 mL min-1. The temperatures of the transfer line and ion 
source were 200 °C and 260 °C, respectively. Mass ions 
were detected in the full scan range of 50-600 m/z. SCARs 
were identified by matching the readings against the US 
National Institute of Standards and Technology (NIST) 
library.
Urine was used to identify SCRAs of indole structure, 
such us AB-CHMINACA and its carboxy metabolite. First, 
we ran alkaline hydrolysis by adding of 1 mL of 10 mol L-1 
sodium hydroxide to 10 mL of urine and heating the mix 
to 55 °C in a water bath for 30 min. After the hydrolysis 
and pH adjustment to 4 with 1 mol L-1 hydrochloric acid, 
SCRA metabolites were extracted with diethyl ether. The 
organic layer was evaporated, and dried extracts reconstituted 
in 1 mL of methanol. For SCRAs with indasole structure, 
neutral solid phase extraction was done before analysis. 
After activation of the cartridge with methanol and water, 
1 mL of urine sample was loaded. The cartridge was washed 
with 1 mL of 5 % methanol, and SCRAs were eluted with 
1 mL of methanol. The extracts were analysed with a Waters 
high performance liquid chromatographer / mass 
spectrometer (HPLC-ESI-MS) or a Waters 2695 HPLC 
coupled with Waters photodiode array (PDA) 2696 detector 
(Waters, Milford, MA, USA). The mobile phase for HPLC/
PDA was a mixture of phosphate buffer (pH 3.6) and 
acetonitrile. SCRA metabolites were separated from the 
matrix on a Symmetry C8 column (5 µm, 4.6 x 250 mm, 
Waters) in gradient mode (Table 1).
The SCRAs were identified by their UV spectrum and 
confirmed with a Waters 2695 HPLC coupled with Waters 
ZQ mass spectrometric detector with electrospray 
ionisation. The compounds of interest were separated on a 
Waters XTerra C18 column (3.5 µm, 4.6 x150 mm), which 
was heated to 30 °C. The analytical conditions for the MS 
detector were: capillary voltage 3 kV, ion source temperature 
125 °C, desolvation temperature 430 °C, desolvation 
nitrogen flow 400 L h-1, and nitrogen flow on the cone 
50 L h-1. The mobile phase was a mixture of 5 mmol L-1 of 
ammonium formiate (pH 3.5) (A) and acetonitrile (B) in 
gradient mode (Table 2).
SCRAs and metabolites were identified by their 
characteristic ions. The principal ions for confirmation were 
as follows: AB-CHMINACA m/z 357, 241, 312, 144; AB-
CHMINACA carboxy metabolite m/z 358, 241, 312, 144 
(at the cone voltage of 50 V).
RESULTS
Table 3 shows the signs and symptoms of SCRA 
overdose in the order of their frequency. The most frequent 
signs were tachycardia, mydriasis, and somnolence, while 
the least common symptoms were loss of consciousness, 
pallor, paraesthesia, muscle twitches, and short-term 
memory impairment.
In the tested herbal product “Biljni tamjan” (herbal 
incense) GC-MS identified JWH-122 (Figure 3), and JWH-
210 (Figure 4). 5F-AKB48 was found in the herbal product 
“Galaxy” (Figure 5) and AB-PINACA (Figure 6) in the 
herbal product “Bad-Mad”. MDMB-CHMICA was detected 
in a cigarette (Figure 7). 
Urine HPLC-ESI-MS detected the carboxy metabolites 
of AB-FUBINACA (in three patients), AB-CHMINACA 
(in six patients), and MDMB-CHMICA (in one patient).
To illustrate signs and symptoms of SCRAs overdose 
witnessed at the DRT NPCC we present two typical cases 
below. After receiving symptomatic treatment, all patients 
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Table 1 Composition of mobile phase for HPLC/PDA
Time 
(min)
Flow 
(mL 
min-1)
% A  
(phosphate 
buffer)
% B (aceto-
nytrile) Curve
initial 1.0 85 15 -
3 1.0 85 15 6
9 1.0 65 35 6
28 1.5 20 80 6
30 1.0 85 15 6
Table 2 Composition of mobile phase for LC/MS
Time 
(min)
%A 
(formiate 
buffer)
%B 
(acetonytrile)
Flow 
(mL 
min-1)
Curve
initial 95 5 0.1 1
2 95 5 0.2 6
16 10 90 0.2 6
20 95 5 0.2 5
26 95 5 0.2 5
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had fully recovered within 8 h and were discharged shortly 
afterwards.
Case report 1
A 22-year-old woman was admitted to the DRT NPCC 
after having smoked the herbal product known under local 
name “Biljni tamjan” (herbal incense) bought in a head 
shop. Some 20 minutes after smoking, she was trembling 
and had palpitations, chest pain, and vertigo. On the 
admission she was conscious, oriented, with moderate 
agitation and mydriasis. Her vital signs were as follows: 
blood pressure 160/90 mmHg, pulse 168 min-1, respiratory 
rate 13 min-1, and blood oxygen saturation 98 %. ECG 
showed sinus rhythm with the heart rate of 112 min-1 without 
other changes. GC/MS detected JWH-122 in the herbal 
product (Figure 2). She received 500 mL of a 5 % 
intravenous glucose infusion and 10 mg of intramuscular 
diazepam. She fully recovered within four hours and was 
discharged after the adverse effects of SCRAs withdrew.
Case report 2
A 23-year-old man was admitted to the DRT NPCC 
after having smoked the herbal product “Rainbow”, also 
bought in a head shop. He explained that he wanted to “try 
something new and lift his mood”. Soon after using it, he 
was found in the attic of his house highly agitated, yelling, 
disoriented, with visual hallucinations. On the admission 
he was conscious, disoriented, with agitation and mydriasis. 
His vital signs were as follows: blood pressure 125/75 mmHg, 
heart rate 138 min-1, respiratory rate 14 min-1, blood oxygen 
saturation 96 %. ECG showed sinus rhythm with the heart 
rate of 110 min-1 without other changes. Urine HPLC-ESI-
MS detected the AB-FUBINACA carboxy metabolite. The 
patient received 500 mL of Hartmann’s solution (i.v.) and 
10 mg of intramuscular diazepam. He recovered fully within 
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Table 3 Adverse effects of SCRA overdose in 58 patients treated 
at the NPCC from 2013 to 2016
Adverse effects n (ratio)
Tachycardia 53 (0.914)
Mydriasis 31 (0.534)
Somnolence 16 (0.276)
Nausea 16 (0.276)
Vomiting 16 (0.276)
Agitation 16 (0.276)
Dizziness 10 (0.172)
Disorientation 9 (0.155)
Chest pain 4 (0.069)
Dyspnoea 4 (0.069)
Loss of consciousness 2 (0.034)
Short-term memory loss 2 (0.034)
Paraesthesia 2 (0.034)
Muscle cramps 2 (0.034)
Figure 3 GC/MS chromatogram and mass spectrum of JWH-122 
(“Biljni tamjan” / herbal incense)
Figure 4 GC/MS chromatogram and mass spectrum of JWH-210 
(“Biljni tamjan” / herbal incense)
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five hours and was discharged after the adverse effects of 
SCRAs withdrew.
DISCUSSION
Susceptibility to the effects of SCRAs is individual and 
depends on the intrinsic properties of these substances, their 
concentration in the product, the mode and frequency of 
use, and several other predisposing factors and comorbidities.
The findings and the symptoms observed among our 
patients were in line with the most common adverse effects 
reported in the literature, including agitation, nausea, and 
tachycardia. Less common adverse effects include heart 
attack, seizures, rhabdomyolysis with kidney damage, and 
psychosis (3, 5, 7, 8, 10), but they were not observed among 
our patients.
The growing number of SCRAs on the global and 
national market, their chemical diversity, frequent changes 
in composition, and difficulties that come with the analysis 
of these substances pose a significant challenge for clinical 
toxicologists and forensic services. Routine analysis and 
screening of these substances in biological samples and 
seized materials mainly rely on the analytical methods such 
as GC/MS, HPLC/MS, and immunochemical assays (10, 
16-23).
What often makes the work of forensic and clinical 
services difficult are technical limitations or unwillingness 
of some patients to consent to the analysis. Because of that, 
it is not always possible to detect the specific substance in 
biological samples.
Even so, our findings have confirmed the capability of 
the NPCC to monitor NPS abuse in Serbia, detect them in 
illicit products and biological samples, and clinically 
manage adverse effects in their users.
The NPCC has committed itself to efficiently and 
systematically collect relevant data on synthetic 
cannabinoids and their adverse effects in the future, to 
monitor changes in the purity and composition of controlled 
PS and NPS-based products, and raise the public awareness 
of the NPS so as to improve the effectiveness of the national 
EWS.
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Figure 5 GC/MS chromatogram and mass spectrum of 5F-AKB 
(“Galaxy”)
Figure 6 GC/MS chromatogram and mass spectrum of AB-
PINACA (“Bad-Mad”)
Figure 7 GC/MS chromatogram and mass spectrum of MDMB-
CHMICA (in a cigarette)
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Clinical and analytical experience of the NPCC, 
development and fine-tuning of the existing and the 
implementation of new detection methods, and the exchange 
of information with other key stakeholders nationwide and 
internationally through the EWS in Serbia and EU will help 
to adequately monitor SCRA trends and promptly issue 
necessary legislative measures.
Ethical approval
According to the Medicines and Medical Devices 
Agency of Serbia, retrospective research involving human 
subjects or a patient file research does require the ethical 
approval by the institutional review board (in this case the 
Ethics Committee of the Military Medical Academy).
This research has been performed in accordance with 
the ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments.
Informed consent
For this type of study formal informed consent is not 
required.
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Klinička i analitička iskustva Nacionalnog centra za kontrolu trovanja sa sintetičkim kanabinoidima
U porastu je broj pacijenata koji se zbrinjava zbog predoziranja novim psihoaktivnim supstancijama (NPS), dostupnima 
na ilegalnom tržištu droga u Srbiji. Cilj je ovog rada  prikazati klinička i analitička iskustva Nacionalnog centra za kontrolu 
trovanja (NCKT) sa sintetičkim kanabinoidima (SC) i upozoriti na NPS-ove dostupne na ilegalnom tržištu droga u Srbiji. 
Od siječnja 2013. do prosinca 2016. u NCKT-u je zbog učinaka sintetičkih kanabinoida zbrinuto 58 pacijenata u dobi od 
14 do 25 godina. Njihova je klinička slika uključivala: tahikardiju (53 od 58 pacijenata), midrijazu (31), pospanost, 
mučninu, povraćanje i agitaciju (16), nesvjesticu (10), dezorijentaciju (9), dispneju i bol u prsima (4) te gubitak svijesti, 
bljedilo, parestezije, grčeve u mišićima i kratkotrajni gubitak pamćenja (2). Nakon odgovarajuće simptomatske i suportivne 
terapije u hitnoj službi, svi su se pacijenti potpuno oporavili u roku od osam sati i ubrzo nakon toga otpušteni. Drugi dio 
rada fokusiran je na analizu preparata poznatih pod nazivima “Biljni tamjan”, “Bijeli sljez”, “Rainbow Special”, “Herbal 
incense” itd., i na analizu uzorka urina pacijenata metodom plinske kromatografije s masenom spektrometrijom i tekućinske 
kromatografije visoke djelotvornosti s masenom spektrometrijom. Detektirani su sljedeći sintetički kanabinoidi: AB-
PINACA, JWH-018, JWH-122, JWH-210, 5F-AKB48 i MDMB-CHMICA u biljnim proizvodima i AB-FUBINACA, 
AB-CHMINACA i MDMB-CHMICA u uzorcima urina. Rezultati tih analiza pokazali su da NCKT ima veliki kapacitet 
za I) praćenje zloporabe NPS-a u Srbiji, II) njihovu učinkovitu detekciju u biljnim proizvodima i biološkim uzorcima i 
III) kliničko liječenje toksičnih učinaka u korisnika tih supstancija. Kako bi pridonio učinkovitosti nacionalnog sustava 
ranog upozoravanja, NCKT će u budućnosti sustavno prikupljati relevantne podatke o sintetičkim kanabinoidima i njihovim 
štetnim učincima, detektirati promjenu čistoće i sastava kontroliranih psihoaktivnih supstancija i preparata na bazi NPS-
ova, istodobno podižući svijest javnosti o tim supstancijama. 
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